PMID- 26566289
OWN - NLM
STAT- MEDLINE
DCOM- 20160624
LR  - 20190221
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 10
IP  - 11
DP  - 2015
TI  - Assessment of HER2 Status Using Immunohistochemistry (IHC) and Fluorescence In 
      Situ Hybridization (FISH) Techniques in Mucinous Epithelial Ovarian Cancer: A 
      Comprehensive Comparison between ToGA Biopsy Method and ToGA Surgical Specimen 
      Method.
PG  - e0142135
LID - 10.1371/journal.pone.0142135 [doi]
LID - e0142135
AB  - We aimed to compare the assay performance characteristics of HER2 status in 
      mucinous epithelial ovarian cancer (EOC) by ToGA (Trastuzumab for Gastric Cancer) 
      biopsy versus ToGA surgical specimen methods. Forty-nine tissue microarray (TMA) 
      samples of mucinous EOC from Asian women were analyzed by immunohistochemistry 
      (IHC) and fluorescence in situ hybridization (FISH) tests using ToGA trial HER2 
      scoring methods. The overall concordance between IHC and FISH by the ToGA 
      surgical specimen method is 97.56% and by the ToGA biopsy specimen method is 
      97.14%. The agreements of HER2 IHC results under both biopsy and surgical 
      specimen methods were nearly perfect (weighted kappa = 0.845). Additionally, the 
      percentage of Her2 FISH amplification showed increasing trend with increasing 
      HER2 IHC ordinals (negative, equivocal, positive) by both TOGA biopsy (P<0.001) 
      and surgical specimen method (P<0.001). After excluding equivocal cases, the 
      sensitivity (100%), PPV (88.89%) and NPV (100%) of HER2 IHC were unchanged under 
      either surgical specimen method or biopsy method. However, the specificity 
      (96.97%) and accuracy (97.56%) of HER2 IHC was slightly higher under the surgical 
      specimen method than those (specificity 96.30%, accuracy 97.14%) under the biopsy 
      method. Of the total 49 cases, the number (n = 14) of HER2 IHC equivocal results 
      under the ToGA biopsy method was 1.75-fold higher than those (n = 8) under the 
      ToGA surgical specimen method (28.57% vs. 16.32%). Therefore, compared to ToGA 
      surgery specimen method, the ToGA biopsy method caused more equivocal IHC cases 
      to be referred to FISH testing and did not increase the detection rates of Her2 
      FISH amplification.
FAU - Chao, Wan-Ru
AU  - Chao WR
AD  - Department of Pathology, Chung-Shan Medical University and Chung Shan Medical 
      University Hospital, Taichung, Taiwan.
FAU - Lee, Ming-Yung
AU  - Lee MY
AD  - Department of Statistics and Informatics Science, Providence University, 
      Taichung, Taiwan.
FAU - Ruan, Alexandra
AU  - Ruan A
AD  - Keck School of Medicine of the University of Southern California, Los Angeles, 
      California, United States of America.
FAU - Sheng, Huang Pin
AU  - Sheng HP
AD  - Department of Obstetrics and Gynecology, School of Medicine, Chung-Shan Medical 
      University and Chung-Shan Medical University Hospital, Taichung, Taiwan.
FAU - Hsu, Jeng-Dong
AU  - Hsu JD
AD  - Department of Pathology, Chung-Shan Medical University and Chung Shan Medical 
      University Hospital, Taichung, Taiwan.
FAU - Han, Chih-Ping
AU  - Han CP
AD  - Department of Pathology, Chung-Shan Medical University and Chung Shan Medical 
      University Hospital, Taichung, Taiwan.
AD  - Department of Obstetrics and Gynecology, School of Medicine, Chung-Shan Medical 
      University and Chung-Shan Medical University Hospital, Taichung, Taiwan.
FAU - Koo, Chiew-Loon
AU  - Koo CL
AD  - Department of Pathology, Tungs' Taichung MetroHarbor Hospital, Taichung, Taiwan.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151113
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Biopsy/methods
MH  - Carcinoma, Ovarian Epithelial
MH  - Female
MH  - Gene Amplification
MH  - Gene Dosage
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunohistochemistry/methods
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Neoplasms, Glandular and Epithelial/*genetics/*pathology
MH  - Ovarian Neoplasms/*genetics/*pathology
MH  - Ovary/metabolism/*pathology
MH  - Receptor, ErbB-2/analysis/*genetics
MH  - *Specimen Handling/methods
PMC - PMC4643932
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2015/11/14 06:00
MHDA- 2016/06/25 06:00
PMCR- 2015/11/13
CRDT- 2015/11/14 06:00
PHST- 2015/08/14 00:00 [received]
PHST- 2015/10/16 00:00 [accepted]
PHST- 2015/11/14 06:00 [entrez]
PHST- 2015/11/14 06:00 [pubmed]
PHST- 2016/06/25 06:00 [medline]
PHST- 2015/11/13 00:00 [pmc-release]
AID - PONE-D-15-35701 [pii]
AID - 10.1371/journal.pone.0142135 [doi]
PST - epublish
SO  - PLoS One. 2015 Nov 13;10(11):e0142135. doi: 10.1371/journal.pone.0142135. 
      eCollection 2015.